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Drug (budesonide) detachment during inhalation from crystalline and 
carrier lactose carriers with different rugosities and size fractions was investigated 
over a range of low carrier payloads. It was found that the amount of residual drug 
on the carrier after inhalation (carrier residue: CR) differs between coarse and fine 
crystalline carrier fractions. The difference increases with decreasing carrier 
surface payload (mg/m
2
). This is explained by the existence of pseudo active sites 
(smooth crystal planes where adhering drug particles are exposed to press-on 
forces during mixing). Such press-on forces increase the interparticulate forces 
between the drug and carrier particles in mixtures with coarse carrier fractions. 
Measurements with an ISF inhaler showed similar trends in CR as found for the 
test inhaler, only the detachment was lower because the ISF inhaler generates has a 
less effective de-agglomeration principle. Granular carriers can provide shelter 
from press-on forces, because drug particles can be stowed in their surface cavities. 
It has been found that the degree of sheltering depends on the type and volume of 
the carrier surface cavities, as well as on the mixing conditions. The smaller the 
cavities and the milder the mixing process are, the higher the fraction of drug 
becomes that is detached during inhalation. However, the relevance of these 
parameters depends strongly on the carrier payload. Therefore, careful balancing 
between carrier payload, carrier surface topography and mixing conditions will be 







 Recently, some new highly potent anti-asthma drugs have been marketed. 
The reduction in dose to amounts smaller than 20 µg is further stretching the 
performance requirements for the dry powder formulations used for these drugs. 
For instance, formoterol fumarate (Novartis Foradil
®
) in a metered mass of 25 mg 
requires a carrier payload of only 0.05% to obtain a dose of 12 µg (Schlimmer, 
2002; Dubois et al., 2003). Also tiotropium bromide (Boehringer Spiriva 
HandiHaler
®
) is a highly potent active substance given in a dose of 18 µg as a dry 
powder (Dahl et al., 2003). Also with these low carrier payloads a sufficiently high 
and reproducible fine particle fraction must be obtained. In a previous study, it was 
shown that drug particle detachment from (lactose) carrier crystals during 
inhalation tends to deteriorate when the drug concentration in the adhesive 
mixtures is decreased. This was observed was for all (crystalline) carrier size 
fractions at a high flow rate, and particularly for fine carriers at a moderate flow 
rate (Dickhoff et al., 2003). The deterioration started already at payloads > 0.4% 
(w/w). One way to cope with this problem is to reduce the metered mass. For 
instance, the metered mass of tiotropium bromide is approx. 3.5 mg. As a result, 
the drug concentration in the formulation is kept at 0.5% (w/w), which is still 
acceptable from the viewpoint of drug redispersion during inhalation. However, 
low metered masses are not always possible. There is a limit to the amount of 
powder mixture that can be metered by, or discharged from the inhaler dose 
mechanism during inhalation accurately, and the limit may be different for 
different inhaler designs. Dry powder inhalation also finds increasing interest for 
the pulmonary delivery of systemically active agents (Ganderton, 1992) like 
peptides and proteins (Niven et al., 1994; Patton et al., 1999). In contrast with the 
previously mentioned new anti-asthma drugs, such active substances are given in a 
high dose, particularly when they have to be stabilized with sugar glass technology 
before they can be administered as a dry powder (Skyler et al., 2001; Maa et al., 
2004). In sugar glass formulations, the excipient in the solid dispersion with the 
drug determines largely the dose weight given. Also antibiotics like colistin 
sulfomethate and tobramycin in cystic fibrosis therapy are administered in high 
dose ranges (160 to 300 mg). With these developments, the total range of carrier 
payloads in adhesive mixtures for inhalation has to be extended dramatically. 
Developments in dry powder inhalation technology also include the 
introduction of new inhaler types. These new inhalers may have different 





 (Schering-Plough) and Novolizer
TM
 
(Viatris) generate inertial separation forces instead of turbulent shear or frictional 
forces. Inertial forces enable successful detachment of drug particles not only from 
smooth carrier surfaces, but also from carrier irregularities. Therefore, these new 
inhalers have generally higher de-agglomeration efficiencies than most currently 
available devices and a high carrier rugosity may not be a problem (de Boer et al., 
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2003; Dickhoff et al., 2005). Consequently, much coarser carrier fractions can be 
used as the carrier applied in turbulent shear inhalers, which improves the dose 
accuracy. In fact, very fine carrier fractions do not always perform best in these 
new inhalers because a certain residence time in the classifier of the Novolizer
TM
 or 
in the cyclone of the Airmax
TM
 is required to make maximal use of the available 
energy within the inhaled air stream. Generally, the residence time in the cyclone 
type of circulation chambers decreases with decreasing mean carrier diameter as a 
result of a decreasing ratio of centrifugal force to drag force (de Boer et al., 2003). 
Coarse carrier particles normally have a higher surface rugosity than fine carrier 
particles, because the size of surface discontinuities of (industrially produced) 
carrier crystals increases with the diameter of the crystal. A high carrier rugosity 
may reduce the efficacy of inertial and frictional press-on forces during mixing 
which increase the interparticulate (drug-to-carrier) forces in the mixture (Dickhoff 
et al., 2005). Drug agglomerates tend to accumulate in the carrier surface cavities 
during mixing where they find shelter from these press-on forces. Besides, drug 
agglomerates in cavities are exposed to much higher inertial separation forces 
during inhalation than single drug particles (Louey et al., 2003). Obviously, this 
may contribute to a greater drug particle detachment. Therefore, carriers with a 
high surface rugosity may be advantageous for the new generation of inertial 
separation inhalers, but the optimal conditions for this sheltering have not yet been 
found. These conditions are related to parameters such as size and shape of the 
carrier irregularities and the mixing conditions. If the carrier cavities are too large, 
or if the mixing is too violent (or too long), agglomerates inside these cavities may 
also be detached during the mixing process and be redistributed over the carrier 
surface, where they become in reach of the press-on forces. Finally, the sheltering 
capacity (storage volume) has to be balanced in relation to the desired carrier 
payload (Dickhoff et al., 2005). 
 Summarizing, it can be concluded that new drug and inhaler developments 
require extension of the investigations on the effects of carrier payload and carrier 
rugosity. In previous studies, we have focussed particularly on the higher drug 
concentrations, up to and including 8% (w/w) (Dickhoff et al., 2003; 2005). The 
aim of this study is to investigate the drug detachment during inhalation with a 
classifier based test inhaler for mixtures with payloads in the range between 0.05 
and 4% (w/w) for crystalline and granular carriers. Granular carriers with 
differently sized surface discontinuities were used for this study. Additionally, the 
mixing conditions (with a Turbula mixer) for these granular carrier fractions were 
varied from mild (20 rpm) to relatively violent (90 rpm) in order to establish the 
optimum conditions. To investigate the general applicability of our observations 
and conclusions experiments were also carried out with a different inhaler, having 





5.3. Materials and methods 
 
5.3.1. Starting materials 
Three different carrier fractions (63-90, 150-200 and 250-355 µm) of 
crystalline alpha lactose monohydrate were derived from Pharmatose 80M (DMV 
International, Veghel, The Netherlands). The fractions were obtained by 30 min 
vibratory sieving (Fritsch Analysette 3, Germany) followed by 20 min of air jet 
sieving (Alpine A200, Augsburg, Germany). Pharmatose 100M, 200M, 325M and 
450M were used to make granules with different surface textures. Micronized 
budesonide was supplied by Sicor (Milan, Italy). The volume median diameter 
(VMD = X50) of the budesonide used was 1.42 µm (X10: 0.60 µm, X90: 2.96 µm). 
 
5.3.2. Lactose granulation and preparation of carrier size fractions 
Granular carrier materials with different rugosities were prepared by 
agglomeration of different crystalline lactose starting materials (100M, 200M, 
325M and 450M). Granulation was performed in a batch size of 1 kg, using a high 
shear mixer granulator Gral 10 (Machines Collette, Wommelgem, Belgium) and 
160 ml of water as binder liquid added at a rate of 20 ml/min. Impeller and chopper 
speed were adjusted to 600 rpm and 3000 rpm respectively, and after wetting, a 
kneading phase of 3 min was applied in order to obtain dense and strong 
agglomerates. After kneading, the wet mass was passed through an oscillating 
sieve with an aperture of 2 mm (Erweka, AR 4000, Heusenstamm, Germany) and 
dried in an oven at 40°C for 16 hrs. 250-355 µm sieve fractions were prepared as 
described for the crystalline carriers. 
 
5.3.3. Characterisation of the starting materials 
Particle size distributions of the starting materials were measured with a 
Sympatec HELOS compact KA laser diffraction apparatus (Sympatec GmbH, 
Clausthal-Zellerfeld, Germany), using a RODOS dry powder disperser (at 3.0 bar). 
Lenses of 100 mm (for the budesonide sample) and 200 mm (for the lactose 
fractions) were used and calculations were based on the Fraunhofer theory. All data 
given are the mean of at least three measurements.  
The surface texture of the carrier fractions has been expressed as a ‘surface 
roughness index’ (SRI), which is the ratio of the specific surface area from nitrogen 
adsorption to the calculated surface area. Nitrogen adsorption (BET theory 
Branauer et al., 1938) was performed with a Tristar surface analyser 
(Micromeritics Instrument Corporation, Norcross, USA). Samples of approx. 1 g 
were inserted in test tubes and flushed with helium gas at 20°C for 2 h, prior to 
measurement. The calculated surface areas have been based on the arithmetic mean 
of the sieve fractions, assuming that particles are spherical. 
The amount of impurities on the surface of the lactose crystals was 
measured with UV adsorption, using a UNICAM UV 500 (ThermoSpectronic, 
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Cambridge, UK) at 280 nm of a 5% aqueous lactose solution. Because solutions 
were clear, filtration was not necessary. 
 The Hausner ratio (Hausner, 1967) was computed as the ratio of the bulk 
density after tapping to that before 200 taps using an Engelsman Jolting volumeter 
(Ludwigshafen, Germany).  
 
5.3.4. Mixture preparation and homogeneity testing 





a Turbula mixer (W.A. Bachofen, T2C, Basel, Switzerland) at 20 or 90 rpm for 10 
min (batch size: 25 g). Mixtures with crystalline carrier fractions contained 0.05; 
0.1; 0.2; 0.4; 1.0; 1.5 and 2.0% (w/w) budesonide, and mixtures with granular 
carriers contained 0.1; 0.2; 0.4; 1.0; 2.0 and 4.0% (w/w) of the same drug.  
For calculation of the percent coverage of the carrier surface with drug 
particles, it was assumed that all (drug and carrier) particles are spherical and 
monodisperse with a diameter that equals volume median diameter (X50-value) 
from laser diffraction analysis for the drug particles, and the arithmetic mean of the 
sieve fraction for the carrier particles. It was also assumed that the projection of 
each drug particle on the carrier surface is a square with a side that has the same 
length as the diameter of the particle (leaving 21.5% of the carrier surface 
uncovered). 
Homogeneity was determined on 20 samples of 25 (± 1.0) mg per mixture. 
The samples were dissolved in 20 ml ethanol p.a. and the UV adsorption was 
measured at 243.7 nm, using a UNICAM UV 500 (ThermoSpectronic, Cambridge, 
UK). 
 
5.3.5. Inhalers and carrier residue 
The test inhaler (University of Groningen, The Netherlands) used for the 
inhalation experiments has been described previously (Dickhoff et al., 2003). This 
test inhaler has an air classifier type of de-agglomeration principle (inertia), which 
separates particles upon size. Theoretical cut-off values for crystalline (1 aq) 
lactose are 27 and 19 µm at 30 and 60 l/min respectively. The test inhaler has no 
dose system: individual doses of 25 mg were weighed and inserted manually. 
Large particles (or unbroken pellets) are retained and stay in circulation as long as 
there is an air stream through the classifier. After inhalation, the retained carrier 
particles were removed from the device and analysed for residual drug (carrier 
residue).  
 An ISF inhaler has been used as marketed reference inhaler (Salvatore, 
1976). Powder de-agglomeration in this inhaler is primarily by turbulent shear 
(drag and lift forces). Furthermore carrier particle impaction against the inner wall 
of the capsule circulation chamber after discharge from the capsule may contribute 
somewhat to de-agglomeration. For the ISF inhaler individual doses of 25 mg were 
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weighed and filled in sealed inhalation capsules nr. 3. The first stage deposition 
during cascade impactor analysis was considered to represent the carrier residue. 
 
5.3.6. Laser diffraction analysis of the aerosol cloud 
Size analysis of the particles in the aerosol cloud from the test inhaler was 
performed with the same laser diffraction apparatus as described for 
characterization of the starting materials. The test inhaler was connected to a 
previously described inhaler adapter with flow control unit (de Boer et al., 2002). A 
lens of 100 mm was used and the start of each measurement was triggered on an 
optical signal of 0.05% on channel 30 and stopped after 3 s real measuring time. 
The flow rate through the test inhaler was adjusted to 10, 20 and 30 l/min, 
respectively. Each value presented, is the mean of ten doses and for each individual 
measurement a reference measurement was performed on the carrier without drug, 
in order to make corrections for released lactose fines. 
 
5.3.7. Cascade impactor analyses (CIA) 
In vitro deposition was tested with a Multi-Stage Liquid Impinger (MSLI) 
of the Astra type (Erweka, Heusenstamm, Germany), using the induction port 
described by the European Pharmacopoeia 4
th
 Ed. 2002, with a special coupling 
flange for the test inhaler. Each impactor stage was filled with 20 ml ethanol p.a., 
except for the final stage, in which a 76 mm dry glass filer (Pall Corporation, type 
A/E, Michigan, USA) was inserted. The flow rate through the inhalers was 
adjusted to 30 or 60 l/min on the basis of the differential pressure across the inhaler 
measured at the position of the coupling flange. The inhalation time was 3 s. 
After completion of a series of ten inhalations, the drug fractions on the 
impactor stages were allowed to dissolve for at least 1 h before they were collected. 
The drug solutions were processed in the same way as described for homogeneity 
testing. Fractions derived from the stages 3 and 4 and the filter are referred to as 
the fine particle fraction. All data given are the mean of two series of ten doses. 
The in vitro aerosol deposition studies were conducted in an air conditioned room, 
where the ambient temperature and relative humidity (RH) were 19 ± 1ºC and 50 ± 
5% respectively. 
 
5.4. Results and discussion 
All mixtures prepared for this study showed a good homogeneity. The 
coefficient of variation for the drug content was below 3.3%, which is well within 
the recommended value of 4-5% (Dietrick, 1993). Table 1 summarizes some 
























80M (63-90 µm) 0.055 0.1713 3.36 0.0509 1.08 1.20 
80M (150-200 µm) 0.041 0.1607 7.22 0.0223 1.84 1.13 




5.4.1. The effect of carrier payload on particle detachment during inhalation 
Fig. 1 presents the carrier residue (CR) as a function of the carrier payload 
at 30 and 60 l/min for mixtures with crystalline carrier fractions. Initially CR for all 
three carrier fractions decreases relatively quickly with increasing payload at both 
flow rates. Starting at a payload of approx. 0.4% (30 l/min) the decrease rates slow 
down and the curves start to diverge from each other. When the payload is further 
is increased, CR for the coarse fraction rises again, whereas the decrease in CR for 
the fine fraction is further continued at a slower rate. The intermediate size fraction 
shows an intermediate behaviour. The differences in slope within the range of 
payloads between 0.4 and 2% may seem relatively small, but they are the 
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Fig. 1: Carrier residue as function of the carrier payload (% budesonide) from different 
crystalline lactose carrier crystals (■ and □ 63-90, ○ and ● 150-200 and ▲ and ∆ 250-355 




The reason for this difference in behaviour between different carrier size 
fractions at higher payloads has been discussed previously (Dickhoff et al., 2003). 
A decreasing CR with increasing payload is the result of an increasing excess of 
drug particles relative to the number of strong bonding places (active sites). This 
reduces the mean adhesive force in the mixture between the drug and carrier 
particles. Basically, this is the same for all carrier size fractions. Yet, for a coarse 
crystalline carrier, CR starts to exhibit a different behaviour at payloads above 
0.4% (w/w). This may be attributed to the action of inertial and frictional press-on 
forces during mixing. Such forces make the interactive forces in the mixture higher 
and are the result of carrier particle collisions in the mixing container. As explained 
before, the magnitude of these forces depends on the carrier diameter. 
In Fig. 1, CR decreases with increasing payload in a comparable way for 
all three carrier size fractions at 30 l/min. The difference in specific surface area 
between the carrier fractions makes direct comparison of drug partition into 
fractions attached to weak and strong bonding sites difficult however. Therefore, 
Fig. 2 has been prepared which shows CR as function of the initial surface payload 
(in mg per square meter of carrier surface). In contrast with Fig. 1, the CR-curves 
for the coarsest and finest carrier differ increasingly from each other with 
decreasing payload (starting at a payload of approx. 300 mg/m
2
). This suggest that 
the distribution of drug over low and high binding sites is balanced differently 
between both carrier fractions at a low payload, which could be the result of a 
higher bonding capacity of the active sites for the coarse fraction. The CR-values at 
60 l/min do seem to contradict this however. At this flow rate, when only particles 
attached to the strongest bonding (active) sites are not dislodged, CR is nearly the 
same for all fractions. When the removal forces during inhalation are sufficiently 
high, the increase in press-on forces is apparently no longer sufficient to influence 
the fraction of drug detached. This leads to the conclusion that the adhesive forces 
for drug particles (attached to the weak bonding sites) that have been increased by 
press-on forces are lower than the adhesive forces between drug particles that are 
attached to active carrier sites. The results in Fig. 2 at 60 l/min also suggest that the 
balancing of drug over strong and weak binding sites is approx. the same for all 
carrier size fractions and so are the number of active sites for these fractions. The 
absolute values for CR within the range of payloads between 0.4 and 2% in Fig. 1 
are somewhat different from those reported in a previous study, which may be a 
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Fig. 2: Carrier residue (%) as function of the initial surface payload (mg/m
2
) from different 
crystalline lactose carriers (■ and □ 63-90, ○ and ● 150-200 and ▲ and ∆ 250-355 µm). 
Closed symbols refer to 30 l/min; open symbols to 60 l/min (n=2). 
 
If the fraction of particles that remains attached at 60 l/min (CR) is approx. 
the same for all carrier size fractions (as shown in Fig. 2), and the size distributions 
for the drug particles that are not attached to the active carrier sites are the same 
too, a decrease in the flow rate should cause the same shift in CR towards higher 
values for all carrier fractions. This, because the ratio of removal (FR) to adhesive 
forces (FA) changes in a same way for all fractions. The finding that this does not 
occur (Fig. 2), means that the size distributions of the adhesive forces for particles 
attached to weak bonding places are different for the different fractions. This can 
be explained with the action of press-on forces at low payloads on so-called 
‘pseudo active sites’. Pseudo active sites here are defined as smooth crystal planes 
that make contact with each other during the mixing process when carrier particles 
collide with, or roll over each other. They do not have a high binding potential of 
their own, at least not compared with the active sites in terms of places where 
increased contact areas or multiple contact points are possible. But particles 
attached to such planes are subjected to the inertial and frictional press-on forces 
during mixing, which increases the drug-to-carrier interaction forces compared to 
carrier sites where these press-on forces are not effective. It is known from the 
literature and previous studies that drug particles are wiped together in carrier 
surface discontinuities during the course of the mixing process (Kulvanich and 
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Stewart, 1987; Iida et al., 2003). However, initially, a random distribution of drug 
particles over all types of carrier sites is more likely. Obviously the attachment 
forces of particles initially deposited on smooth planes may increase most strongly 
in mixtures with coarse carrier particles. Therefore, pseudo active sites exist 
primarily for coarse carrier size fractions. They do increase the total number of 
strong binding places and by that, the number of drug particles that is necessary to 
get the same carrier residue as obtained for mixtures with fine carrier fractions at 
the same carrier surface payload. This explains why the CR-curves for the coarse 
and fine carrier fraction deviate from each other at low payloads when low de-
agglomeration forces are applied. 
 
5.4.2. The effect of carrier rugosity on drug particle detachment during 
inhalation 
Particles may be sheltered from the press-on forces during mixing in 
carrier surface discontinuities (Dickhoff et al., 2003; 2005). The sheltering capacity 
and efficacy depend on the type and volume of the discontinuities and the mixing 
process respectively. It has been shown that granular carriers, with a high surface 
rugosity, exhibit an increased storage capacity (Dickhoff et al., 2005). A high 
rugosity does not necessarily guarantee a high sheltering efficacy however. During 
mixing, large drug agglomerates may be removed from the carrier surface cavities 
again by action of the same type of forces that also occur during inhalation. 
Additionally, extremities of granular structures may be able to project into the 
cavities of neighbouring carrier particles in the mixture. Therefore, not only the 
total volume of the carrier discontinuities is important; also the size and shape of 
the individual pores could be relevant. Moreover, our hypothesis implies that there 
should also be an effect of the mixing conditions. Fig. 3 shows the carrier residues 
as a function of the payload for four different granular structures, having the same 
size fraction of 250-355 µm. A similar initial decrease in CR as for crystalline 
carriers has been obtained, but the minimum occurs at a much higher payload 
(between 1 and 2% w/w). Also the minimum CR-values of most granules are 
slightly lower than that for the crystalline size fraction of 250-355 µm (Fig. 1), 
which supports the theory of the existence of pseudo active sites. Specifically, in 
granular structures there are less smooth crystal planes that are accessible to press-
on forces. This is best shown in Fig. 4 which compares a crystalline carrier with 
two granular carriers composed of primary particles with different median 
diameters. The crystalline carrier has the lowest storage volume (sheltering 
capacity) for the drug (shaded areas) and the largest smooth crystal planes on its 
outer circumference. These large crystal planes are the pseudo active sites. The 
coarse granular structure has an increased sheltering capacity and reduced area for 
pseudo active sites. The fine granular structure has approx. the same storage 
volume as the coarse granule, but the drug agglomerates inside the individual pores 
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are much smaller (increased sheltering efficacy), whereas there are only few 
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Fig. 3: Carrier residue as function of the carrier payload (% budesonide) from different 
granular carriers made from: ■ 100M, ♦ 200M ▲ 325M and × 450M, at 30 l/min. 
 
 
Fig. 4: (A) a coarse crystalline carrier (B) a granule which has large cavities and (C) a 
granule which has small but many cavities. 
 
The results in Fig. 3 are in agreement with predictions. The highest carrier 
residue has been obtained for the granules with the largest primary particles 
(Pharmatose 100M), and therefore largest pores. The large drug agglomerates in 
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these pores, with high masses, are subjected to the highest inertial forces, not only 
during inhalation Louey and Stewart, 2002, but also during mixing of all 
agglomerate carriers. This results in the highest degree of drug redistributed over 
circumferential crystal planes during mixing, and thus the highest effect of the 
press-on forces during mixing. The minimum in CR for the 100M granulate is also 
obtained at a relatively low carrier payload compared with the other mixtures in 
Fig. 3. Because there exists no method to characterize the drug storage capacity 
and efficacy adequately, the ratio of median drug diameter to median primary 
particle diameter in the granule (both obtained from laser diffraction analysis) has 
been used to distinguish between the different granular carriers. Fig. 5 shows the 
minimum value for CR (trough value), as well as the payload at which this trough 
is found as function of this ratio. To obtain the precise minimum values for CR, 
fitting has been applied on the curves in Fig. 3 (using hyperbolic functions). It can 
clearly be seen that the interesting range of diameter ratios is between 0 and 20 (to 
40) under the mixing conditions used. In this respect, the 100M granule is not an 







































Fig. 5: Carrier residue (CR) when the trough is reached (■) and payload at which the trough 
occurs (▲) as function of the diameter ratio between the size of the primary particles of the 
granule (X50 from laser diffraction) and the size of the primary particles of budesonide (X50 
from laser diffraction).  
 
5.4.3. The effect of mixing conditions on drug detachment during inhalation 
If large drug agglomerates can be removed from the carrier surface cavities 
during mixing, mixing intensity must have an effect. In a similar way as during 
inhalation, it may be expected that the extent of drug relocation depends on the 
magnitude of the inertial forces that are responsible for this removal. Fig. 6 proves 
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that this is indeed true for two different payloads of 0.4 (A) and 4.0% (B) w/w. In 
these figures the results from cascade impactor analysis (30 l/min) are presented for 
mixtures prepared using two different mixing intensities (20 and 90 rpm) in the 
Turbula mixer. In addition to the carrier residue, the stage 3, 4 and filter 
depositions are shown. It should be mentioned that the test inhaler used for the 
experiments was not designed for drug delivery to the respiratory tract, but for 
carrier residue experiments only. As a consequence, mouthpiece accumulations are 
quite high.  
Fig. 6A indicates that coarse granular carriers have hardly any advantage 
over crystalline carriers at a relatively low payload of 0.4% when violent mixing 
conditions are applied. In the same size fractions of 250-355 µm, granules 
composed of smaller primary particles do have a much larger surface area to which 
drug particles can adhere. Consequently, the excess of drug particles relative to the 
number of active bonding sites is much lower. The precise effect of this aspect is 
difficult to assess however, as it is opposite to that of a reduced number of pseudo 
active sites. When larger drug agglomerates are being removed from the carrier 
cavities during mixing (at 90 rpm) and divided into smaller portions (or even 
primary particles), the redistribution of drug particles over the entire carrier surface 
may be relatively high. If however the mixing intensity is reduced (to 20 rpm), the 
removal forces are decreased, larger drug agglomerates remain within the cavities 
of the granular structure. This leads to reduced occupation of (pseudo) active sites 
and higher removal forces during inhalation. This explains why the CR, for 
mixtures prepared at 20 rpm, is approx. 50% of the value obtained at 90 rpm (for 












































































Fig. 6: Percentage deposition at two different mixing intensities for mixtures of a carrier sieve 
fraction of 250-255 µm with a payload of 0.4% (w/w) (A) and 4.0% (w/w) (B) at a flow rate of 
30 l/min. (80M is a crystalline carrier, 100M and 450M are granular carriers). 
 
At 4.0% (Fig. 6B) payload there is an advantage of granular structures for 
both mixing intensities (at least for air classifier type of inhalers). In contrast to the 
lower payload, there is also an advantage of lower mixing intensity for the 
crystalline carrier. The reasons have already been explained. For a crystalline 
carrier, reduction of the mixing intensity is a reduction of the press-on forces that 
increase the interaction forces in the mixture. For the granular carriers, there is a 
reduced disintegration of large drug agglomerates into smaller agglomerates that 
have a lower inertia and are subjected to lower inertial removal forces during 
inhalation. Fig. 6 confirms that maximal drug detachment (during inhalation) from 
granular carriers must be obtained from selecting the optimal combination of 
carrier payload, type and volume of the carrier surface pores and mixing 
conditions. Under these conditions, a CR of only 20% is possible at a relatively low 
inspiratory flow of 30 l/min, as shown for the 450M granulate prepared at 20 rpm 
in a Turbula mixer with a payload between 0.4 and 4.0% w/w. Although Fig. 6 
shows that an increase in the mixing intensity from 20 to 90 rpm increases the 
carrier residue of granular carriers dramatically, there appears to be no influence of 
carrier pore size on this increase, which is somewhat surprising. For both granular 
carriers (100 and 450M), as well as, at both payloads, the increase in carrier residue 
is approx. a factor of 2. 
 
5.4.4. The effect of inhaler design on drug detachment during inhalation 
Results in this study so far have been obtained using inertial separation 
forces for the drug particles during inhalation. To investigate whether similar 
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trends can be found when other types of separation forces (in different inhaler 
designs) are applied, an ISF inhaler has been used for detachment experiments with 
the two extreme crystalline carrier fractions in Fig. 1 (63-90 and 250-355 µm 
respectively) at 30 and 60 l/min. For this inhaler, drug particle detachment from 
carrier crystals is mainly the result of turbulent shear (drag and lift forces), 
although a minor contribution from inertial forces may not be excluded. Carrier 
particles impact mildly with each other and with the inner walls of the capsule 
while the capsule rotates during inhalation. Particles may also collide somewhat 
more violently with the inner wall of the circulation chamber upon discharge from 
the capsule, but this is only a single collision. Because the ISF inhaler does not 
retain the carrier particles, the first stage deposition in the MSLI has been measured 
to asses the fraction of drug not detached during inhalation. Considering that the 
cut-off value for the first stage of this impactor is 23.8 µm at 30 l/min, it may be 
expected that all carrier particles are collected on the first stage.  
Fig. 7 shows these first stage depositions (CR values) for the same 
mixtures as used for Fig. 1. All CR-values are much higher than in Fig. 1, 
particularly at 60 l/min, but the observed trends are largely the same. Initially, CR 
decreases with increasing drug concentration in the mixture, whereas at higher 
payloads CR of the mixture with the coarsest carrier starts to increase again. The 
higher CR-values at all payloads and for both flow rates (compared to Fig. 1) 
confirm that inertial forces are more effective in detachment of drug particles from 
carrier crystals during inhalation than drag and lift forces. However, the reduction 
of removal forces for all mixtures, does not change the relative differences in 
performance between the mixtures that are controlled by the size distributions of 
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 stage deposition as function of the carrier payload (% budesonide) from different 
lactose carrier crystals (■ and □ 63-90 and ▲ and ∆ 250-355 µm). Closed symbols refer to 
30 l/min; open symbols to 60 l/min, n=2, with an ISF inhaler. 
 
5.5. Conclusions 
 The present study shows that application of very low payloads, in adhesive 
mixtures, for dry powder inhalation is unfavourable. It has been explained that this 
is due to an excess of active sites relative to the amount of drug particles present in 
the formulation. In the range of payloads < 0.4% w/w, the carrier surface properties 
seem to be of greater significance than the bulk properties to drug particle 
detachment. The adhesive forces between drug and carrier particles, which are 
increased by press-on forces during mixing, are of smaller than those between drug 
particles and the active sites of the carrier particles. At least, the influence of the 
press-on forces is not noticeable after increase of the inhalation flow rate from 30 
to 60 l/min. 
Coarser crystalline carriers generate larger press-on forces during mixing 
than the finer carriers. This results in the existence of pseudo active sites on their 
smooth surfaces, which explains why at lower payloads increasing differences 
occur in the detachment from coarser and finer carriers. For agglomerated carriers 
the occurrence of larger crystal planes on the circumference of the agglomerate 
where press-on forces may be effective is reduced compared to crystalline carriers. 
In this study, it has been shown that coarse granular carriers have an 
advantage over crystalline carriers (with the same size) at a relatively high payload 
of 4% when inertial separation forces are applied during inhalation. Drug particles 
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in the surface cavities of granular carriers find better shelter from the action of the 
press-on forces during mixing. At lower payloads, the advantage is confined to 
mild mixing conditions. Under violent mixing conditions, drug particles are 
distributed more effectively over the entire surface area of the granular structures, 
which is larger than that of crystalline carriers at the same size. Consequently, the 
excess of active sites relative to the number of drug particles is larger than that for 
crystalline carriers. All results considered, it may be concluded that it depends on 
the balancing between the carrier payload, the type and shape of the carrier surface 
irregularities and the mixing conditions whether granular carriers are an advantage 
or not (for inhalers generating inertial separation forces). The optimal combination 
of conditions is difficult to predict however, because of the opposite effects from 
increasing the specific surface area (binding capacity of the active sites) and 
increasing the sheltering capacity. Finally, it can be concluded from the 
experiments with the ISF inhaler, that the factors that increase the interparticulate 
forces in the mixture (active sites and press-on forces) are also relevant to inhalers 
that rely primarily on turbulent shear for drug redispersion during inhalation.  
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